Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

European Journal of Preventive Cardiology

Volumn 25, Issue 5, 2018, Pages 495-502

  Usman, Muhammad Shariq ^a   Siddiqi, Tariq Jamal ^a   Memon, Muhammad Mustafa ^a   Khan, Muhammad Shahzeb ^b   Rawasia, Wasiq Faraz ^c   Talha Ayub, Muhammad ^b   Sreenivasan, Jayakumar ^b   Golzar, Yasmeen ^b  

^a Dow University of Health Sciences (DUHS)   (Pakistan)

^b Division of Cardiology   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

cardiovascular outcomes; diabetes mellitus; meta analysis; SGLT2; Sodium glucose co transporter

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE ASSESSMENT; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR ADVERSE CARDIAC EVENT; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS; CAUSE OF DEATH; COMPLICATION; GLOBAL HEALTH; INCIDENCE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; HUMANS; INCIDENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SURVIVAL RATE;

EID: 85042796850     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487318755531     Document Type: Article

References (27)

1. Khalil CA, Roussel R, Mohammedi K, Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Prev Cardiol 2011; 19: 374–381.
2. Tang H, Fang Z, Wang T, Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol 2016; 118: 1774–1780.
3. Zinman B, Wanner C, Lachin JM, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
4. Neal B, Perkovic V, Mahaffey KW, Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
5. Arnold SV, Inzucchi SE, Tang F, Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® Research to Practice project. Eur J Prev Cardiol 2017; 15: 1637–1645.
6. Saad M, Mahmoud AN, Elgendy IY, Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol 2017; 228: 352–358.
7. Wu JH, Foote C, Blomster J, Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411–419.
8. Hutton B, Salanti G, Caldwell DM, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–784.
9. Higgins JP, Altman DG, Gøtzsche PC, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928–d5928.
10. Turnbull FM, Abraira C, Anderson RJ, Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–2298.
11. Hayward RA, Reaven PD, Wiitala WL, Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197–2206.
12. Holman RR, Paul SK, Bethel MA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
13. Gerstein HC, Miller ME, Genuth S, ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818–828.
14. Fitchett D, Zinman B, Wanner C, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526–1534.
15. Norhammar A, Mellbin L, Cosentino F. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol 2017; 24: 52–60.
16. Chilton R, Tikkanen I, Cannon CP, Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 1180–1193.
17. Sattar N, McLaren J, Kristensen SL, SGLT2 inhibition and cardiovascular events: why did EMPA-REG OUTCOMES surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1333–1339.
18. ClinicalTrials.gov. Safety and effectiveness of SGLT-2 inhibitors in patients with heart failure and diabetes. https://clinicaltrials.gov/ct2/show/NCT02397421 (2015, accessed 10 September 2017)
19. ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events. https://clinicaltrials.gov/ct2/show/NCT01730534 (2012, accessed 10 September 2017)
20. Liu XY, Zhang N, Chen R, Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications 2015; 29: 1295–1303.
21. Yang T, Lu M, Ma L, Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Eur J Clin Pharmacol 2015; 71: 1325–1332.
22. Sun YN, Zhou Y, Chen X, The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 2014; 4: e004619–e004619.
23. Packer M, Anker SD, Butler J, Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017; 2: 1025–1029.
24. Pessoa TD, Campos LC, Carraro-Lacroix L, Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 2014; 25: 2028–2039.
25. Inoue BH, dos Santos L, Pessoa TD, Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am J Physiol Regul Integr Comp Physiol 2012; 302: R166–R174.
26. Joubert M, Jagu B, Montaigne D, The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 2017; 66: 1030–1040.
27. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiacfibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 2017; 104: 298–310.